Pharma Focus Asia

Alector Launched Breakthrough Latozinemab Antibody for Progranulin Gene Mutation (FTD-GRN)

Alector has introduced atozinemab, a groundbreaking investigational human monoclonal antibody crafted to obstruct sortilin, thereby boosting progranulin (PGRN) levels, offering promise in treating frontotemporal dementia with a progranulin gene mutation (FTD-GRN).

Meanwhile, Latozinemab (AL001) represents another investigational human monoclonal antibody tailored to regulate progranulin (PGRN), a pivotal regulator of brain immune activity associated with various neurodegenerative disorders such as frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. Latozinemab seeks to enhance PGRN levels by inhibiting sortilin, a receptor involved in PGRN degradation.

Frontotemporal dementia (FTD) is a rare yet significant neurodegenerative condition, often leading to early onset dementia. Its impact is felt by an estimated 50,000 to 60,000 individuals in the United States and approximately 110,000 in the European Union, with potentially higher prevalence rates in Asia and Latin America.

Latozinemab emerges as the frontrunner among progranulin-elevating candidates in FTD-GRN development, earning the prestigious designation as the first investigational medicine to receive breakthrough therapy recognition for treating Progranulin Gene Mutation (FTD-GRN).

Alector announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to latozinemab, an investigational human monoclonal antibody designed to block sortilin, thereby elevating progranulin (PGRN) levels.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024